Abstracts tagged "Lupus nephritis"

Abstract Number: 665 • 2017 ACR/ARHP Annual Meeting
Low Vitamin D Is Associated with End Stage Renal Disease in Systemic Lupus Erythematosus
Michelle Petri¹, Wei Fu² and Daniel Goldman², ¹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vitamin D insufficiency/deficiency is common in SLE. Replacement therapy may help renal disease activity. We asked whether low vitamin D predicted later organ damage.…
Abstract Number: 668 • 2017 ACR/ARHP Annual Meeting
Is Uric Acid Level a Predictor of Long-Term Renal Outcome in Lupus Nephritis?
Michelle Lopes¹, Samara Gavinier², Elaine Leon², Vilma Viana², Eduardo Ferreira Borba¹ and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Hyperuricemia has been reported to be associated with chronic kidney disease (CKD) in several clinical conditions, and recent studies also observed an association between…
Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting
A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy
Marco Ulises Martinez-Martinez¹, Cesar Eduardo Vallín Orozco², David Martínez-Galla³ and Carlos Abud-Mendoza⁴, ¹Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ²Rheumatology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ³Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, ⁴Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
- Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…
Abstract Number: 672 • 2017 ACR/ARHP Annual Meeting
Baseline Hyperuricemia As a Predictive Value for Development of Lupus Nephritis in Premenopausal SLE Patients
Doo-Ho Lim¹, Seokchan Hong², Ji Seon Oh³, Yong-Gil Kim², Chang Keun Lee², Seung Won Choi¹ and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, National Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Although lupus nephritis is a common and serious manifestation of SLE, there have been few predictive markers for development of lupus nephritis in SLE…
Abstract Number: 99 • 2017 Pediatric Rheumatology Symposium
PILOT STUDY MEASURING HEPCIDIN AND ARTERIAL STIFFNESS IN CHILDREN WITH SLE AND LUPUS NEPHRITIS
Sangeeta Sule¹, Sarah Joo² and Meredith Atkinson², ¹Pediatrics, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Cardiovascular disease (CV dz) is common in SLE and lupus nephritis (LN), but premature atherosclerosis risk does not appear to be linked to classic…
Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Michael Bennett¹, Qing Ma², Jun Ying³, Prasad Devarajan¹ and Hermine Brunner⁴, ¹Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
Abstract Number: 92 • 2017 Pediatric Rheumatology Symposium
Mycophenolate Mofetil is an Effective Induction Therapy Agent in Childhood-onset Pure Membranous Lupus Nephritis
Maria Pereira¹, Eyal Muscal², Marietta DeGuzman³, Anna Carmela Sagcal-Gironella⁴ and Scott E. Wenderfer⁵, ¹Immunology, Allergy & Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁵Pediatrics-Renal, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Treatment guidelines for childhood-onset class V membranous lupus nephritis (MLN) have not yet been established. The addition of mycophenolate mofetil (MMF) has shown improvement…
Abstract Number: 5L • 2016 ACR/ARHP Annual Meeting
Speed of Remission with the Use of Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus Nephritis Study
Mary Anne Dooley¹, William Pendergraft III², Ellen M. Ginzler³, Nancy J. Olsen⁴, James Tumlin⁵, Brad H. Rovin⁶, Frédéric A. Houssiau⁷, David Wofsy⁸, David A. Isenberg⁹, Neil Solomons¹⁰, Robert Huizinga¹¹ and AURA Study Group, ¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²Kidney Center, University of North Carolina, Chapel Hill, NC, ³Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ⁴Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA, ⁵Nephrology, University of Tennessee College of Medicine, Chattanooga, TN, ⁶Ohio State University Medical Center, Columbus, OH, ⁷Rheumatology, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, ⁸Rheumatology, University of California, San Francisco, San Francisco, CA, ⁹Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ¹⁰Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ¹¹Clinical Affairs, Aurinia Pharmaceuticals Inc., Victoria, BC, Canada
Background/Purpose: Voclosporin (VCS) is a novel CNI intended for use in the treatment of autoimmune diseases such as lupus nephritis. VCS’s unique structure allows for…
Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting
Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual
Hironari Hanaoka¹, Hidehiro Yamada², Tomofumi Kiyokawa³, Harunobu Iida¹, Takeshi Suzuki¹, Yoshioki Yamasaki⁴, Seido Ooka⁵, Hiroko Nagafuchi³, Takahiro Okazaki³, Daisuke Ichikawa⁶, Sayuri Shirai⁶, Yugo Shibagaki⁷, Junki Koike⁸ and Shoichi Ozaki³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, ³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁷Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, ⁸Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
Abstract Number: 2827 • 2016 ACR/ARHP Annual Meeting
Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death
Cristina Arriens¹, Sixia Chen², David Karp³, Ramesh Saxena⁴, Kamalanathan Sambandam⁴, Eliza Chakravarty¹, Judith A. James⁵ and Joan T. Merrill⁶, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Internal Medicine/Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Approximately half of SLE patients develop lupus nephritis (LN), a major cause of morbidity and early mortality. It is known that prolonged renal inflammation…
Abstract Number: 2829 • 2016 ACR/ARHP Annual Meeting
Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis
Eleana Ntatsaki¹, Alba Velo Garcia², Alan D. Salama³ and David A. Isenberg⁴, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential…
Abstract Number: 2842 • 2016 ACR/ARHP Annual Meeting
Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
William Fung¹, Jiandong Su² and Zahi Touma³, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) manifests with proteinuria and/or active urine sediment. Renal composite indices include proteinuria, urinary active sediment (RBCs, casts) and serum creatinine.…
Abstract Number: 746 • 2016 ACR/ARHP Annual Meeting
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
Ruth J. Pepper¹, Venkat Reddy², Scott Henderson³ and Maria J. Leandro⁴, ¹UCL Centre for Nephrology, Royal Free Hospital, London, United Kingdom, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³UCL Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patients with lupus nephritis (LN) achieve variable clinical response following Rituximab (RTX) based B-cell depletion therapy, with rituximab treatment aiming to decrease the use…
Abstract Number: 2852 • 2016 ACR/ARHP Annual Meeting
Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Aymeric Couturier¹, Vincent Molinie², Charles Cartou³, Serge ARFI⁴, Violaine Emal-Aglae⁵, Katlyne Polomat⁶, Florence MOINET⁶, Georges JEAN BAPTISTE⁷ and Christophe Deligny⁸, ¹nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ²Pathology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ³nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ⁴University Hospital, CHU Fort de France, Fort de France, Martinique, ⁵Nephrology, Centre Hospitalier de Mangot-Vulcin, Le Lamentin, Martinique, ⁶Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: In African-descent patients, lupus nephritis (LN) lead to a worse outcome than in Caucasians. Long term data are rare in countries where black populations…
Abstract Number: 749 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
Richard Furie¹, Ana Malvar², Sandra V. Navarra³, Karen Smirnakis⁴, Jessica Kong⁴, Nathalie Franchimont⁴ and Fei Shih⁴, ¹Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ²Nephrology Division, Hospital Fernandez, Buenos Aires, Argentina, ³Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁴Biogen, Cambridge, MA
Background/Purpose: The addition of an anti-TWEAK monoclonal antibody to SOC LN therapy did not improve 52-week RR rates in proliferative LN despite observed pharmacodynamic effects.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.